CurrentAetnaPolicy 0431

Enuresis (Nocturnal) Treatments — Clinical Policy Bulletin

This Aetna Clinical Policy Bulletin governs coverage and medical necessity criteria for interventions used to treat nocturnal enuresis (bedwetting), including bedwetting alarms and desmopressin, and lists interventions considered experimental/investigational. It applies to Aetna members and providers submitting claims for these services.

Policy Summary

PayerAetna

PolicyEnuresis (Nocturnal) Treatments — Clinical Policy Bulletin

Policy CodePolicy 0431

Change TypeNo material changes in this revision

Effective DateJul 6, 2000

Next Review DateApr 25, 2024

Key ActionObtain prior authorization when billing S8270 (enuresis alarm) or J2597 (desmopressin) and document age, bedwetting frequency, absence of daytime wetting, prior conservative therapies, and evaluation ruling out organic causes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7alarm min age

3 nights/wkmin frequency

>5desmopressin age

N39.44ICD-10

51%adenotonsillectomy RR

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

inv-01: Bedwetting alarm (durable medical equipment)

Aetna considers the use of a bedwetting alarm as durable medical equipment medically necessary when ALL of the following are met

Bedwetting alarm medical necessity criteria: 1) Member is 7 years of age or older; 2) Member has experienced bedwetting a minimum of 3 nights a week in the previous month OR at least 1 wetting episode weekly for 1 year; 3) Member has no daytime wetting; 4) Member has been examined by a physician and physical or organic causes for nocturnal enuresis (e.g., renal disease, neurological disease, infection) have been ruled out.see individual nodes

If these criteria are not met, use of the enuresis alarm is considered experimental and investigational (not medically necessary).

inv-02: Desmopressin (pharmacologic therapy)

Desmopressin for primary nocturnal enuresis is considered medically necessary when ALL of the following are met

Desmopressin criteria: 1) Child is older than 5 years; AND 2) Bedwetting has not responded to non-pharmacologic therapies (e.g., fluid/food intake advice, enuresis alarm) OR these therapies were refused or the child/family is unlikely to adhere to enuresis alarm treatment.age >5 years

Desmopressin may be used as an alternative to enuresis alarm for rapid or short-term improvement.

inv-04: Initial therapy (alarm or desmopressin)

Covered when ALL of the following are met

Initial therapy (alarm or desmopressin): Patient has nocturnal enuresis and has undergone basic urotherapy/behavioral advice OR urotherapy is unsuitable; then either enuresis alarm or desmopressin may be used as first-line treatment.

Based on guideline and institutional algorithm summaries; bladder training alone is not supported as an effective standalone therapy for nocturnal enuresis.

inv-05: Adenotonsillectomy (T&A)

Considered medically necessary when ALL of the following are met

Adenotonsillectomy for PNE: Child aged 2–19 years with primary nocturnal enuresis and documented sleep-disordered breathing for whom tonsillectomy and adenoidectomy (T&A) is otherwise indicated; expected benefit and risks have been discussed with family.

Observational data show pooled complete resolution rates around 51% with heterogeneity; weigh risks and alternatives when considering T&A for PNE.

inv-03: Experimental and investigational interventions

Aetna considers the following interventions experimental and investigational (not covered) because effectiveness has not been established

Experimental/Investigational interventions: Acupuncture; Bladder training (urotherapy); Chiropractic management; Clonidine; Extracorporeal magnetic innervation therapy; Homeopathy; Hypnosis; Laser acupuncture therapy; Magnetic sacral root stimulation; Rapid palatal expansion; Tonsillectomy; Transcutaneous electrical nerve stimulation; Tuina (massage) therapy; Wearable alarm-assisted urotherapy for daytime urinary incontinence in children.N/A

These interventions are considered experimental/investigational for nocturnal enuresis because effectiveness has not been established.

inv-06: Experimental / limited-evidence therapies

Evidence summary (informational/mixed coverage stance)

Alternative/limited-evidence therapies: Acupuncture, magnetic sacral root stimulation/repetitive sacral root magnetic stimulation (rSMS), rapid palatal expansion, chiropractic manipulation, clonidine, transcutaneous electrical nerve stimulation (TENS) including parasacral TENS, and other approaches have been studied with mixed, limited, or low-quality evidence; some small studies report benefit while higher-quality trials often show no effect or inconsistent results. Desmopressin in non-enuretic populations (e.g., MS) has noted adverse events including hyponatremia in some studies.

Safety profiles and study quality vary; further high-quality research is needed to establish effectiveness and safety for these modalities.

inv-07: Coverage stance by intervention

Evidence summary and coverage stance by modality:

Parasacral TENS (PTENS): Meta-analysis of 4 RCTs (208 children) showed no difference between PTENS and controls (RR 0.70, 95% CI 0.37–1.32); weighted mean full response 10.8% (0–19%). Subgroup analyses (mono-symptomatic NE) showed no clear benefit. Evidence insufficient to establish effectiveness.

Drawbacks include small sample sizes, heterogeneity, prior/concomitant therapies, and low study quality.

Transcutaneous electrical nerve stimulation (general/tibial/foot): Individual studies show mixed results: a small at-home foot TENS study (n=22) reported reduced wet nights and good tolerance, whereas a larger randomized double-blind study found no anti-enuretic effect. Evidence is inconsistent.

Differences in stimulation site, dose, pulse width, and administration setting may account for disparate findings.

Laser acupuncture / Low-level laser therapy (LAT/LLLT): Systematic reviews/meta-analyses (11–13 trials, n≈890–927) report some positive findings for LAT, moxibustion, and acupoint injection versus controls for improvement rates, but overall evidence quality is very low and methodological bias is common; comparisons with desmopressin are inconclusive.

Aetna’s policy notes that special training and skilled care or monitoring services to use the enuresis alarm are not generally considered medically necessary. The policy lists the alarm (HCPCS S8270) as durable medical equipment covered only when the specified medical necessity criteria are met (see bedwetting alarm criteria). Services limited to training, ongoing skilled monitoring, or supervision for use of the alarm are not separately covered under the enuresis alarm benefit.

Randomized double-blind, placebo-controlled evidence does not support a clear anti-enuretic effect for TENS in children with monosymptomatic nocturnal enuresis. In one such trial (Jorgensen et al, 2017) none of the treated children achieved complete remission and there were no significant changes in wet nights, nocturnal urine production, or bladder capacity compared with sham. Small at-home foot TENS studies have reported reductions in wet nights, but higher-quality blinded trials do not show benefit.

The policy identifies several interventions as supported only by very low or inconsistent-quality evidence and therefore experimental/investigational. Examples include parasacral/transcutaneous electrical nerve stimulation (PTENS) when used without documentation of prior guideline-recommended therapies or refractory status, laser acupuncture/low-level laser therapy with heterogeneous parameters and very low GRADE quality, and acupuncture where meta-analyses include low-quality trials. These modalities lack consistent RCT data demonstrating clinically meaningful benefit and are listed as experimental.

The reviewed document does not state any additional explicit exclusions beyond those already described in the policy sections and the experimental/investigational listings. Policy references and the reference list are provided for further detail.

Per the policy, use of a bedwetting alarm when the policy’s medical necessity criteria are not met is considered experimental and investigational (not medically necessary). Coverage is only for alarms meeting the specified criteria (age, frequency, absence of daytime wetting, and physician evaluation ruling out organic causes).

Chiropractic spinal manipulative therapy for nocturnal enuresis is supported primarily by case reports and very low-quality evidence. The policy cites case series and systematic reviews finding insufficient or inconclusive evidence of benefit; GRADE assessments rate the evidence very low, and causality cannot be inferred from case reports. As a result, chiropractic manipulation is listed as experimental/investigational for enuresis.

PTENS (parasacral/transcutaneous electrical nerve stimulation) for mono-symptomatic nocturnal enuresis lacks consistent evidence of efficacy. A meta-analysis of 4 RCTs (208 children) found no difference between PTENS and controls (RR 0.70, 95% CI 0.37–1.32) and a weighted mean full response rate of 10.8%. Subgroup analyses in mono-symptomatic NE also showed no clear benefit. Individual small studies (e.g., at-home foot TENS) reported improvements, but higher-quality randomized trials did not demonstrate anti-enuretic effects.

No explicit additional statements labeling other services as not medically necessary appear in the provided reference chunks beyond the specific 'not medically necessary' and experimental/investigational language already cited in the policy.

Relevant Billing Codes and Coding Notes

Covered HCPCS CodesHCPCSCovered

J2597	Injection, desmopressin acetate, per 1 mcg
S8270	Enuresis alarm, using auditory buzzer and/or vibration device

Covered ICD-10 CodesICD-10Covered

N39.44

Nocturnal enuresis

Not Covered / Experimental HCPCS/CPT/HCPCS/OthermixedNot Covered

E0720	Transcutaneous electrical nerve stimulation (TENS) device, 2 lead, localized stimulation
E0730	Transcutaneous electrical nerve stimulation (TENS) device, 4 or more leads, for multiple nerve stimulation
J0735	Injection, clonidine HCl, 1 mg
90880	Hypnotherapy
97124	Therapeutic procedure, 1 or more areas, each 15 minutes; massage
97810	Acupuncture; initial 15 minutes
97811	Acupuncture; each additional 15 minutes
97813	Acupuncture with electrical stimulation; initial 15 minutes
97814	Acupuncture with electrical stimulation; each additional 15 minutes
98940	Chiropractic manipulative treatment, spinal, 1-2 regions

1–10 of 17

1/2

Bedwetting frequency threshold — inv-17

Frequency threshold (recent month)Minimum 3 nights per week in the previous month

Alternative frequency threshold (longitudinal)At least 1 wetting episode weekly for 1 year

Context for threshold useApplies to medical necessity determination for bedwetting alarm coverage

Age thresholds — inv-18

Minimum age for bedwetting alarm7 years or older

Desmopressin indicated ageChildren older than 5 years when non-pharmacologic therapies have failed or are unsuitable

Prior Authorization, Documentation, and Clinical Workflow

Prior Authorization

Prior authorization for alarm and desmopressin

Prior authorization is required when billing HCPCS S8270 (enuresis alarm) or J2597 (desmopressin acetate). Ensure documentation shows the member meets policy criteria (age, frequency of bedwetting, absence of daytime wetting, physician exam ruling out organic causes) and that non‑pharmacologic therapies (urotherapy/bladder advice and/or enuresis alarm) were attempted or are unsuitable before desmopressin.

Affected codes: S8270, J2597
Document prior conservative measures (urotherapy, fluid/toileting advice, reward systems) and rationale for chosen therapy

Prior Authorization

Adenotonsillectomy authorization guidance

Adenotonsillectomy (tonsillectomy ± adenoidectomy) has been associated with improvement or resolution of primary nocturnal enuresis in observational studies; pooled complete resolution ~51% with partial resolution in ~20%. Prior authorization may be appropriate and should require documentation of sleep‑disordered breathing diagnosis, correlation of enuresis with SDB, and rationale for surgery addressing enuresis as an expected benefit.

Clinical Background and Evidence Summary

Primary nocturnal enuresis is involuntary urination during sleep in patients who have never achieved sustained dryness and often reflects delayed maturation of nighttime urine suppression, bladder capacity, and arousal mechanisms. First-line management emphasizes behavioral measures and urotherapy, with enuresis alarms and desmopressin as recommended first-line options in many cases; desmopressin is a synthetic vasopressin analog used for children older than 5 years when behavioral measures fail or alarms are unsuitable.

Several experimental or limited-evidence therapies are discussed in the evidence sections to provide context. These include PTENS and general TENS approaches with mixed results, acupuncture and laser acupuncture with low-quality trial data and methodological bias, and magnetic sacral root stimulation or rapid palatal expansion where small or uncontrolled studies suggest possible benefit but high-quality RCTs are lacking. The policy presents these as informational summaries that underpin the decision to list such modalities as experimental or investigational.

Definitions and Terms

Monosymptomatic nocturnal enuresis (MNE) — inv-36

DefinitionNocturnal enuresis without additional daytime voiding symptoms

SynonymMonosymptomatic nocturnal enuresis (MNE)

Evaluation noteUrodynamic, radiologic and endoscopic evaluations are not necessary in children with MNE when history and exam are typical

Primary nocturnal enuresis — inv-37

DefinitionEnuresis in patients who have never achieved a sustained period of dryness

Distinguishing featureContrasts with secondary nocturnal enuresis which occurs after a sustained dry period

Clinical course

Policy Dates and Revision History

2023-06-28Last reviewLatest

Policy underwent routine clinical review (Last Review documented).

2000-07-06Effective date

Policy became effective on this date (policy established).

2024-04-25Next scheduled review

Next routine policy review scheduled on this date (planned future review).

Policy Summary

PayerAetna

PolicyEnuresis (Nocturnal) Treatments — Clinical Policy Bulletin

Policy CodePolicy 0431

Change TypeNo material changes in this revision

Effective DateJul 6, 2000

Next Review DateApr 25, 2024

SourceLink

On This Page

Laser parameters and study methods varied widely; further high-quality RCTs needed.

Tuina (pediatric massage): Current evidence is limited; systematic review protocols exist but efficacy and safety remain to be established pending completed reviews.

Wearable alarm-assisted urotherapy and standard urotherapy: Standard urotherapy is defined by ICCS as first-line and includes education, bladder habit training, lifestyle advice, and symptom registration; systematic reviews find low-quality and heterogeneous evidence with reported dryness rates from 0% to 92%. Wearable alarm systems as an adjunct showed non-significant pooled effect for daytime functional urinary incontinence and have adherence limitations.

Standard urotherapy or alarm therapy should generally be attempted/documented prior to experimental/adjunctive modalities.

Clinical implication

Age thresholds are required elements of documentation to support medical necessity

Relevant CPT: 42820, 42821, 42825, 42826

Require documentation: diagnosis of SDB, prior medical management, and explanation linking T&A to expected enuresis improvement

Prior Authorization

Prior authorization recommended for PTENS/LAT

Given limited and inconsistent evidence for parasacral TENS (PTENS) and low‑quality evidence for laser acupuncture therapy (LAT), prior authorization is recommended before approving PTENS or LAT for enuresis. Require prior trial and documentation of standard first‑line therapies and justification for advanced modalities.

PTENS evidence: meta-analysis shows no clear benefit (RR 0.70, 95% CI 0.37–1.32) across included RCTs
LAT evidence: some RCTs show improvement but overall quality is low; further high‑quality trials needed
Affected HCPCS/CPT: potential device codes E0720/E0730; verify coding and medical necessity

Note

Desmopressin references

Desmopressin is a first‑line pharmacologic option for monosymptomatic nocturnal enuresis in children older than 5 years when non‑pharmacologic measures (fluid/toileting advice, enuresis alarm) have failed, are refused, or are unsuitable. For nocturia in adults with neurologic disease (e.g., MS), evidence suggests possible benefit but with notable adverse event rates.

Reference evidence: UpToDate review (Tu & Baskin) and DiBianco et al. support desmopressin as first-line pharmacologic therapy
For MS/nocturia: systematic review (Phe et al. 2019) showed decreased nocturia in some studies but AE rates (including hyponatremia up to 23.5%) and low overall evidence quality

Step Therapy

Therapy sequencing

Therapy sequencing: start with non‑pharmacologic measures (urotherapy/bladder advice and enuresis alarm) as first‑line. If alarm therapy is ineffective after an adequate trial (~3 months), consider escalation to combination therapy or pharmacologic therapy (desmopressin) depending on clinical factors and family preference.

First‑line options: enuresis alarm or desmopressin (when alarm unsuitable or declined)
If alarm fails after ~3 months, consider desmopressin or combination therapy

Step Therapy

First‑line therapy sequencing

First‑line therapy sequencing: many guidelines recommend initiating urotherapy (basic bladder advice) then offering the enuresis alarm and/or desmopressin as first‑line treatments. Evidence does not strongly support routine daytime bladder training alone to reduce nocturnal enuresis; starting directly with alarm or desmopressin is reasonable.

Urotherapy components: education, regular voiding, optimal toilet posture, lifestyle advice
Evidence: RCTs show bladder advice did not significantly reduce wet nights versus alarm alone

Documentation Required

Step‑up from standard urotherapy/alarms

Step‑up from standard urotherapy/alarms: before authorizing advanced or adjunctive modalities (PTENS, LAT, adenotonsillectomy for enuresis), document a prior trial of standard urotherapy and alarm‑based interventions, duration and response, and rationale for escalation.

Document trial duration and adherence to enuresis alarm (typically ≥3 months)
Record objective measures: bedwetting frequency, voiding diary, prior interventions tried and outcomes

Documentation Required

Safety monitoring documentation risk

Safety monitoring and documentation risk: desmopressin carries risk of adverse events including hyponatremia (reported up to 23.5% in small studies of MS patients) as well as headache, nausea, fluid retention, and nasal symptoms. Clinical monitoring and documentation of informed consent, baseline electrolyte assessment when indicated, and vigilance for hyponatremia symptoms are recommended.

Document counseling on hyponatremia risk and fluid‑restriction instructions during therapy
Consider baseline and follow‑up serum sodium in higher‑risk patients (e.g., very young, comorbidities, concomitant medications)

Denial Risk

No explicit denial triggers are present

No explicit denial triggers are specified in the source review apart from standard medical necessity criteria. Coverage determinations should follow the policy's stated criteria (age, frequency, absence of daytime wetting, physician exam ruling out organic causes, prior conservative therapy) and consider evidence quality for advanced therapies.

Interventions considered experimental/investigational per policy (e.g., acupuncture, TENS, LAT, tonsillectomy for enuresis) should be handled per policy guidance and may be denied if criteria for medical necessity are not met
Ensure coding aligns with coverage (see CPT/HCPCS lists)

Primary nocturnal enuresis often reflects delayed maturation and frequently resolves spontaneously over time

Desmopressin — inv-38

DefinitionA synthetic vasopressin analog used as a first-line pharmacologic treatment for nocturnal enuresis in children older than five when behavioral measures fail or alarms are unsuitable

IndicationAlternative to enuresis alarms for rapid or short-term improvement or when alarms fail/refused

Required documentationUse for children >5 years requires documentation that non‑pharmacologic therapies failed, refused, or are unsuitable

Urotherapy / bladder training — inv-39

DefinitionDaytime bladder advice including regular voiding, proper voiding posture, and sufficient fluid intake

Role in managementRecommended as part of initial urotherapy but not supported as an effective standalone therapy for nocturnal enuresis

Clinical noteEnuresis alarm or desmopressin are generally recommended first-line rather than bladder training alone

PTENS / parasacral TENS — inv-40

DefinitionTranscutaneous electrical nerve stimulation applied to parasacral or tibial/foot regions intended to modulate neural inputs to bladder control

Study contextStudied as at-home or clinic-based nightly sessions with varying stimulation sites and protocols

Evidence summaryMeta-analysis of 4 RCTs (208 children) showed no clear benefit of PTENS versus controls; evidence insufficient to establish effectiveness

LAT / LLLT (laser acupuncture therapy) — inv-41

DefinitionLow-level laser therapy applied to acupuncture points (red/infrared wavelengths, continuous waves) used as a non-invasive alternative to needle acupuncture

Study findingsSystematic reviews (11–13 trials, ~890–927 participants) report some improvement with LAT/LLLT but overall evidence quality is very low and heterogeneous

Research needOptimal laser parameters and higher-quality RCTs are needed to establish efficacy and comparative effectiveness versus desmopressin

monosymptomatic nocturnal enuresis term references — inv-42

Usage in literatureTerm 'monosymptomatic nocturnal enuresis' is referenced in multiple ICCS standardization documents and studies for children without daytime symptoms

Clinical relevanceUsed to identify patients for whom urodynamic/endoscopic testing is usually unnecessary and for whom alarm or desmopressin are first-line options

Synonyms and sourcesReferenced in International Children's Continence Society documents and standard reviews cited in policy references